TRIB, US8964385046

Trinity Biotech stock: $9.5 million credit amendment disclosed

Published on 11/20/2026 at 01:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Trinity Biotech stock faces revised financing terms after a credit amendment with Perceptive. The filing also resets key security terms.

Credit amendment raises financing focus

  • Trinity Biotech amended its term-loan agreement with Perceptive Credit Holdings III.
  • The filing highlights liquidity covenant breaches and revised conversion and warrant terms.
  • The company sells diagnostics and develops wearable biosensor products across international markets.
TRIB, US8964385046, Illustration mit AI erstellt.

Trinity Biotech disclosed on November 12 that it had amended its term-loan credit agreement with Perceptive Credit Holdings III on November 6. The company's Form 6-K described the amendment as a total investment of approximately 9.5 million US dollars, including approximately 4.0 million US dollars of new debt funding and approximately 5.5 million US dollars of capitalized interest.

Liquidity waiver adds financing risk

The lenders agreed to waive specified minimum-liquidity covenant noncompliance for June through October 2026, subject to conditions. The filing states that the company and certain subsidiaries had not complied with the covenant during June, July and August. The minimum-liquidity covenant remains in force after the amendment.

The transaction also amended a senior convertible note by reducing its minimum conversion price to 10.00 US dollars per ADS. Applicable outstanding warrants held by Perceptive entities received an exercise price of 5.90 US dollars per ADS. The terms give Trinity Biotech additional funding while leaving investors focused on liquidity, debt obligations and potential future dilution.

Diagnostics and biosensors form core

Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes-management solutions, including wearable biosensors. It develops, acquires, manufactures and markets diagnostic reagents and instruments for point-of-care and clinical-laboratory use. Its products address infectious diseases and haemoglobin A1c and other chemistry parameters, while sales reach customers directly in the United States and through distributors and strategic partners in more than 100 countries.

Irish base supports global reach

Trinity Biotech plc is headquartered in County Wicklow, Ireland, and combines diagnostic products with a developing biosensor business. The company's international distribution network gives it a broader reach than a single-market diagnostics specialist, while its wearable-biosensor activities add a growth-oriented segment alongside its established laboratory and point-of-care products.

Trinity Biotech company facts

  • Company: Trinity Biotech plc
  • ISIN: US8964385046
  • Ticker: TRIB
  • Exchange: Nasdaq
  • Headquarters: County Wicklow, Ireland
  • Business: Human diagnostics, diabetes management and wearable biosensors

Trinity Biotech's Irish home market places the financing update in a European healthcare setting; current market reports provide broader context.

More news and analyses on Trinity Biotech stock.

Disclaimer...
en | US8964385046 | TRIB | boerse | 70538220 | bgmi